Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 560 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 560 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60. Following the sale, the senior vice president directly owned 14,752 shares of the company’s stock, valued at $1,411,913.92. This represents a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total transaction of $128,467.65.

Oruka Therapeutics Price Performance

NASDAQ ORKA traded down $3.73 on Tuesday, hitting $92.20. 784,617 shares of the stock were exchanged, compared to its average volume of 741,278. Oruka Therapeutics, Inc. has a 52-week low of $14.66 and a 52-week high of $115.51. The company has a market capitalization of $6.10 billion, a price-to-earnings ratio of -45.42 and a beta of -0.34. The company’s 50-day moving average price is $95.87 and its two-hundred day moving average price is $72.78.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

ORKA has been the topic of several research analyst reports. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors have recently made changes to their positions in ORKA. Nykredit A S bought a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd bought a new position in Oruka Therapeutics during the fourth quarter valued at approximately $67,000. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the second quarter valued at approximately $91,000. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 178.5% in the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after acquiring an additional 2,033 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Oruka Therapeutics by 119.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock worth $156,000 after acquiring an additional 1,736 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.